Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Nephros Inc (NEPH)

Nephros Inc (NEPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,935
  • Shares Outstanding, K 10,544
  • Annual Sales, $ 14,240 K
  • Annual Income, $ -1,580 K
  • 60-Month Beta 1.34
  • Price/Sales 1.64
  • Price/Cash Flow N/A
  • Price/Book 2.73
Trade NEPH with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.20
  • Growth Rate Est. (year over year) +499,600.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.06 +12.86%
on 03/18/24
3.26 -28.75%
on 03/01/24
-0.77 (-25.00%)
since 02/28/24
3-Month
2.06 +12.86%
on 03/18/24
4.00 -41.88%
on 01/02/24
-1.16 (-33.38%)
since 12/28/23
52-Week
1.05 +121.43%
on 03/31/23
4.04 -42.50%
on 12/28/23
+1.29 (+123.56%)
since 03/28/23

Most Recent Stories

More News
Nephros to Present at LD Micro Main Event XVI

South Orange, New Jersey--(Newsfile Corp. - September 19, 2023) - Nephros, Inc. (NASDAQ: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets,...

NEPH : 2.33 (+2.42%)
Nephros to Present at LD Micro Invitational XIII

South Orange, New Jersey--(Newsfile Corp. - May 24, 2023) - Nephros, Inc. (NASDAQ: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today...

NEPH : 2.33 (+2.42%)
Nephros Inc. (NEPH) Reports Q3 Loss, Misses Revenue Estimates

Nephros Inc. (NEPH) delivered earnings and revenue surprises of 0% and 4.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

NEPH : 2.33 (+2.42%)
CGC : 9.30 (-2.62%)
Nephros Announces Results for Quarter Ended June 30, 2022

Second Quarter Net Revenue of $2.9 Million, a 27% Year-Over-Year Increase;Active Customer Sites Climb 21% to New Record SOUTH ORANGE, NJ, Aug. 10, 2022...

NEPH : 2.33 (+2.42%)
Nephros Second Quarter 2022 Financial Results Conference Call

SOUTH ORANGE, NJ, July 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc.(Nasdaq: NEPH), a leading water technology company providing...

NEPH : 2.33 (+2.42%)
Nephros Announces Preliminary Results for Quarter Ended June 30, 2022 and Projects Positive Net Cash Flow in 12 Months

Second Quarter Revenue of $2.9 Million, Year-Over-Year Increase of 27%;Number of Active Customer Sites Climbs 21% Year-Over-Year SOUTH ORANGE, NJ, July ...

NEPH : 2.33 (+2.42%)
Nephros Receives FDA 510(k) Clearance for HDF Assist Module

The First and Only FDA-Cleared Device Available in the United States to Provide Hemodiafiltration Therapy to Dialysis Patients SOUTH ORANGE, NJ, May 17,...

NEPH : 2.33 (+2.42%)
Nephros Inc. (NEPH) Reports Q1 Loss, Misses Revenue Estimates

Nephros Inc. (NEPH) delivered earnings and revenue surprises of -53.85% and 25.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

NEPH : 2.33 (+2.42%)
VIVO : 33.97 (unch)
Nephros Announces Results for Quarter Ended March 31, 2022

First Quarter Net Revenue of $2.2 Million;Active Customer Sites Climb 17% to New Record SOUTH ORANGE, NJ, May 04, 2022 (GLOBE NEWSWIRE) -- via...

NEPH : 2.33 (+2.42%)
Nephros First Quarter 2022 Financial Results Conference Call

SOUTH ORANGE, NJ, April 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc.(Nasdaq: NEPH), a leading water technology company providing...

NEPH : 2.33 (+2.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Nephros develops advanced End Stage Renal Disease, or ESRD, therapy technology and products that would address both patient treatment needs and the clinical and financial needs of the treatment provider.

See More

Key Turning Points

3rd Resistance Point 2.27
2nd Resistance Point 2.27
1st Resistance Point 2.27
Last Price 2.33
1st Support Level 2.27
2nd Support Level 2.27
3rd Support Level 2.27

See More

52-Week High 4.04
Fibonacci 61.8% 2.90
Fibonacci 50% 2.55
Last Price 2.33
Fibonacci 38.2% 2.19
52-Week Low 1.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar